Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed the atezolizumab plus bevacizumab combination versus sunitinib in metastatic renal cell carcinoma (RCC) patients, were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week.

In the IMmotion151 clinical trial, the combination of atezolizumab plus bevacizumab improved progression-free survival versus sunitinib (11.2 months versus 7.7 months respectively). These data were reported earlier in the year at the ASCO-GU 2018 meeting.

Patient reported outcomes were evaluated to document the patient perspective on overall clinical benefit for each treatment. Patients completed the MD Anderson Symptom Inventory (MDASI) and Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 (FKSI-19) questionnaires on days 1 and 22 of each 6-week treatment cycle, at the end of treatment, and during the follow-up period. Health-related quality of life (HRQoL) was also assessed.

Patients receiving atezolizumab plus bevacizumab reported milder and more stable symptoms, less interference of symptoms with daily life, delayed time to deterioration, and better health-related quality of life compared to patients taking sunitinib.  A greater proportion of patients on the combination reported no or little bother from treatment side effects versus sunitinib-treated patients.

Patient-reported outcomes data from the IMmotion151 clinical trial suggest the atezolizumab plus bevacizumab combination maintained daily functioning with minimal symptom interference, improved health-related quality of life, and delayed time to deterioration versus sunitinib.

Read the ASCO abstract here